Rationale: Tumor necrosis factor receptor-associated factors (TRAFs) are cytoplasmic adaptor proteins for the TNF/interleukin-1/Toll-like receptor superfamily. Ligands of this family comprise multiple important cytokines such as TNF␣, CD40L, and interleukin-1␤ that promote chronic inflammatory diseases such as atherosclerosis. We recently reported overexpression of TRAF5 in murine and human atheromata and that TRAF5 promotes inflammatory functions of cultured endothelial cells and macrophages.
A therosclerosis is one of the leading causes of death worldwide. The concept that inflammatory and immunologic mechanisms drive atherogenesis emerged from both extensive laboratory studies and from clinical observations demonstrating associations between biomarkers of inflammation and cardiovascular events. 1, 2 These findings have spurred the quest for antiinflammatory or immunomodulatory treatments to fight atherosclerosis and its sequelae. Selective modulation of key signaling pathways may afford a fruitful strategy to achieve that goal.
Tumor necrosis factor (TNF) receptor-associated factors (TRAFs) represent important signal transducers for the TNF/ interleukin (IL)-1/Toll-like receptor (TLR) superfamily, several members of which potently promote atherogenesis. We and others found expression of TRAFs in cells typically resident in the atherosclerotic plaques. [3] [4] [5] [6] However, only a few reports have investigated TRAF-dependent functions in the context of vascular disease: TRAF3 and TRAF2 have been implicated in transducing shear stress, 7, 8 and Luo et al recently demonstrated that activation of TNFR2 mediates ischemia-induced atherogenesis by inducing TRAF2-dependent survival pathways. 9 Endothelial cells (ECs) and smooth muscle cells from unstable plaque regions of human carotid arteries overexpress TRAF4. 4 TRAF6 promotes neointima formation on balloon injury in the carotid artery of mice as well as development of in-stent stenosis in rab-bits. 10, 11 In accord, Donners et al observed reduced neointima formation and leukocyte infiltration on carotid artery ligation in mice lacking the binding site for TRAF6 on CD40 on leukocytes. 12 The same group recently showed that these mice crossed with Apolipoprotein E-deficient mice develop significantly smaller atherosclerotic lesions on a high-cholesterol diet (HCD). 13 Finally, we recently reported attenuation of atherogenesis in mice deficient for TRAF1. 14 These findings suggest that TRAFs participate in vascular disease, but the function of TRAF5 in this context remains unsettled.
Two independent groups identified TRAF5 as a 64-kDa protein interacting with LT␤R (lymphotoxin ␤ receptor) and CD40. 15 Further studies implicated TRAF5 with the activation of CD30, CD27, LMP-1 (latent membrane protein 1), HVEM (herpes virus entry mediator), Ox40, 4-1BB, doublestranded RNA-dependent protein kinase PKR, and NIK (nuclear factor B kinase). 16, 17 TRAF5 contains a RING finger followed by 5 Zn 2ϩ finger motifs at its N terminus, crucial for downstream signaling and the conserved TRAF domain at its C terminus, needed for self-association and recognition of cognate receptors. Both TRAF2 and TRAF5 participate in nuclear factor (NF)B and c-Jun N-terminal kinase (JNK) signaling on engagement of TNFR1, CD30, and CD40. 18 Increasing evidence indicates that impairment of JNK and NFB activation resulting from TRAF5 deficiency can be compensated for by TRAF2 and vice versa. 19 However, a nonredundant role for TRAF5 has been recently postulated in LMP-1-mediated JNK activation, 20 as well as glucocorticoid tumor necrosis factor receptor (GITR)-induced NFB, extracellular signal-regulated kinase (ERK)1/2, and p38 stimulation. 21 TRAF5-deficient mice displayed impaired CD40-stimulated B-cell proliferation and mild defects in affinity maturation of IgG antibodies. 22 Our group recently showed overexpression of TRAF5 in human and mouse atheromata and dependency of CD40L and TNF␣-induced IL-6 expression in ECs and macrophages on TRAF5 in line with a proinflammatory role. 3 Therefore, this study tested the hypothesis that TRAF5 deficiency attenuates murine atherogenesis in vivo.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
In Vivo Study
TRAF5-deficient mice were back-crossed 5 times to C57/BL6 (The Jackson Laboratory) and crossed with LDLR Ϫ/Ϫ mice (The Jackson Laboratory). Eight-week-old male littermates of TRAF5 Ϫ/Ϫ / LDLR Ϫ/Ϫ and TRAF5 ϩ/ϩ /LDLR Ϫ/Ϫ consumed HCD for 18 weeks (Ssniff based on Research Diets D12108). Fetal liver cell (FLC) transplantations for evaluation of TRAF2 function in atherosclerosis were performed similarly as previously described. 23 At the end of the study, mice were harvested and histologically analyzed as described previously. 14, 24, 25 
Cell Isolation and Culture
Murine ECs, thioglycollate-elicited peritoneal macrophages, and bone marrow-derived macrophages (BMMs) were isolated and cultured as described previously. 3 Murine leukocytes for flow cytometric analysis were isolated from blood obtained by retroorbital bleeding. For generation of murine splenocytes, mice were euthanized and their spleens harvested and crushed.
Western Blotting
Murine ECs and BMMs were stimulated with TNF␣ (20 ng/mL) and IL-1␤ (10 ng/mL) for 24 hours, lysed, separated by SDS-PAGE under reducing conditions, and blotted to poly(vinylidene difluoride) membranes as described previously. 3 Western blots were analyzed densitometrically using ImageJ (NIH).
Enzyme-Linked Immunoabsorbent Assay
Mouse keratinocyte-derived chemokine (KC) and monocyte chemoattractant protein (MCP)-1 were analyzed in the supernatants of cell cultures using commercially available ELISA Kits (R&D) according to the instructions of the manufacturer.
Flow Cytometry
Cells were washed in 0.1% BSA and preincubated with mouse Fc-Block (␣CD16/32, ebioscience) before antibodies were added. Intracellular staining for FoxP3 was performed using the mouse T-cell regulatory staining kit (ebioscience). Samples were analyzed with a fluorescence-activated cell sorter (FACS Calibur, Becton Dickinson). The mean fluorescence indices (MFI) were quantified using the FlowJo software.
Cytometric Bead Assay
For analysis of inflammatory markers and chemokines, the cytometric bead assay for murine inflammation and chemokines (BD) was used. For detection of p-JNK, p-ERK, and p-p38 the murine signaling cytometric bead assay was used.
Dynamic Adhesion Assays
Dynamic adhesion assays in the flow chamber were performed as described previously. 25 Adherent and rolling leukocytes were filmed under the microscope and counted by blinded investigators. 
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Cell-Spreading Assay
Actin polymerization was evaluated in murine peritoneal macrophages as previously described. 14 
Intravital Microscopy
Mice were anesthetized with ketamine and xylazin, intraperitoneally injected with 200 ng of murine TNF␣, and the cremaster muscle was prepared as described previously. 26 Venules with diameters between 30 and 50 m were observed and recorded through a high sensitivity camera system (AxioCam MRm, Carl Zeiss), and adhering and rolling leukocytes were quantified by blinded investigators.
Lipid-Uptake Assay
BMMs were isolated as described above. After differentiation, cells were starved for 2 hours and stimulated with 10 g/mL Alexa488-labeled acetylated LDL in RPMI for 1 hour. Analysis was performed by fluorescence-activated cell sorting (FACS).
Quantitative RT-PCR of Murine Samples
Total RNA was isolated from organs according to a modified TRIzol protocol and transcribed to cDNA, and targets were analyzed by quantitative RT-PCR as detailed in the Online Data Supplement.
Immunologic Testing
T-cell proliferation and activation were quantified by FACS using antibodies against KLRG-1, CD62L, and CD44 (ebioscience) in response to ␣CD2/CD28 stimulation. Intracellular expression of IL-2, TNF␣, and interferon-␥ was quantified by FACS (BD Pharmingen).
Data Analysis
Data of at least 3 experiments were pooled and presented as meansϮSEM. Statistical analysis used the Student's 2-tailed t test for paired or unpaired values (where appropriate). A probability value of Յ0.05 was considered statistically significant.
Clinical Study
A total of 325 patients undergoing coronary angiography were included in the Tumor Necrosis Factor in Cardiovascular Risk Study (TRAFICS), registered as UKF000748, and approved by the local Institutional Review Board of the University of Freiburg. Patients were divided into 3 groups: no coronary heart disease (No CHD), stable coronary heart disease (CHD), and acute coronary syndrome (ACS). TRAF5 and GAPDH transcripts were quantified by real-time RT PCR and analyzed as detailed in the Online Data Supplement.
Results
TRAF5 Deficiency Accelerates Atherosclerosis in Mice
To test the hypothesis that TRAF5 modulates murine atherosclerosis in vivo, TRAF5 Ϫ/Ϫ /LDLR Ϫ/Ϫ and TRAF5 ϩ/ϩ / LDLR Ϫ/Ϫ mice consumed HCD for 18 weeks. All mice appeared healthy, reproduced according mendelian ratios, and had no obvious abnormalities and a normal life span. Weights and leukocyte counts did not differ at the end of the study. Cholesterol and triglyceride levels did not differ at baseline between both groups but were slightly higher in TRAF5 Ϫ/Ϫ LDLR Ϫ/Ϫ animals after HCD (NՆ10 per group, PՅ0.05; Online Table I) .
Surprisingly, TRAF5-deficient animals developed significantly larger atherosclerotic plaques in aortic roots (0.113Ϯ0.01 mm 2 versus 0.163Ϯ0.02 mm 2 , NՆ12 per group, Pϭ0.02, Figure 1A ) and arches (0.051Ϯ0.01 mm 2 versus 0.133Ϯ0.02 mm 2 , NՆ8 per group, Pϭ0.01, Figure 1B ) compared with control animals on consumption of HCD.
Similar results were obtained in en face analysis of abdominal aortas (NՆ16, Figure 1C ). Analysis of composition revealed most prominently an increase in macrophage content in aortic TRAF5
Ϫ/Ϫ /LDLR Ϫ/Ϫ plaques (Pϭ0.005). Lipid content tended to increase, whereas collagen, smooth muscle cells, and T-cell numbers remained unchanged (Figure 2A through 2D). These features resemble those associated with unstable plaques in humans. 27
TRAF5 Deficiency Promotes Rolling and Adhesion of Inflammatory Cells
During early atherogenesis leukocytes roll and adhere to activated endothelium before migrating into the intima. TRAF5 deficiency on either ECs or leukocytes enhanced adhesion by up to 198Ϯ10% compared with wild-type controls in the flow chamber (NՆ3 each, PՅ0.05, Figure  3A ). We also observed significantly increased rolling of leukocytes in the same model (NՆ3 each, PՅ0.05, Figure  3A ). Accordingly, in vivo adhesion of leukocytes to the endothelium was significantly enhanced in TRAF5-deficient mice on intraperitoneal injection of 200 ng TNF␣ (NՆ3 per group, PՅ0.05; Figure 3B ) as assessed by intravital microscopy. Rolling also tended to increase in this model (NՆ3 per group, Pϭ0.13; Figure 3B ).
Interactions of adhesion molecules on ECs with integrins on immune cells represent the main underlying mechanism of adhesion. TRAF5-deficient ECs expressed significantly more intercellular adhesion molecule (ICAM)-1 compared with respective controls (Nϭ9, PՅ0.05, Figure 4A ). Alike, TRAF5-deficient aortic tissue expressed significantly more VCAM-1 and by tendency more ICAM-1 transcripts, as assessed by quantitative RT-PCR (NՆ3, Figure 4B ). TRAFdeficient monocytes also expressed higher amounts of CD49d, a component of VLA-4, the ligand for VCAM-1, involved in both rolling and firm adhesion (NՆ3, Pϭ0.004, Figure 4C ).
TRAF5 Deficiency Enhances Migration and the Expression of Chemokines
To test whether TRAF5 also modulates in vivo migration, we induced sterile peritonitis by instillation of 4% thioglycollate in TRAF5
Ϫ/Ϫ /LDLR Ϫ/Ϫ and TRAF5 ϩ/ϩ /LDLR Ϫ/Ϫ mice. After 72 hours, significantly more inflammatory cells accumulated in the peritoneal cavity of TRAF5 Figure 5A ). Chemokines such as KC and MCP-1 attract leukocytes and additionally cause rapid activation of ␤1-and ␤2-integrins, which pave the way for firm adhesion. Therefore, we analyzed chemokine expression in serum and aortic lysates from TRAF5 Ϫ/Ϫ /LDLR Ϫ/Ϫ and TRAF5 ϩ/ϩ /LDLR Ϫ/Ϫ mice challenged with TNF␣, demonstrating increased MCP-1 expression in mice deficient for TRAF5 ( Figure 5B and 5C). Similarly, ECs and BMMs, produced significantly more MCP-1 and KC (NՆ8 each, PՅ0.05, Online Figure I, A and B) . In accord, increased MCP-1 and KC expression was detected in aortic plaques from TRAF5-deficient mice on HCD ( Figure 5D and 5E). These data revealed an additional mechanism for enhanced adhesion and augmented atherogenesis in these mice.
TRAF5 Deficiency Increases Macrophage LDL Uptake
Once resident in the intima, monocytes differentiate into macrophages, imbibe modified lipids, and become foam cells. TRAF5-deficient BMMs internalized significantly more fluorescently labeled acetylated LDL than control cells as assessed by fluorescence microscopy and FACS ( Figure 6A ). Mechanistically, we found higher levels of the scavenger receptor CD36 on TRAF5-deficient macrophages compared with controls (Nϭ4, PϽ0.001, Figure 6B ). In contrast, the A through D, Sections of the aortic arches and roots of mice treated as described above were subjected to analysis of macrophage-, smooth muscle cell-, lipid-, and collagen-specific staining. Mac-3-, ␣-actin-, oil red O-, and picrosirius red-positive staining in relation to total wall area is presented as meansϮSEM.
expression of TLR4, also known to mediate modified LDL uptake, was similar between TRAF5-deficient and competent macrophages 28 ( Figure 6C) , and the expression of scavenger receptor A even decreased (NՆ5, Pϭ0.003, Figure 6D ). In blood of TRAF5-deficient animals, ABCA1, another lipid transporter, was significantly increased on monocytes (NՆ5, Pϭ0.025, Figure 6E ).
TRAF5 Deficiency Enhances Actin Polymerization
Differences in adhesion and lipid uptake may also rely on variations of actin cytoskeleton formation. 29 Peritoneal macrophages from TRAF5 Ϫ/Ϫ /LDLR Ϫ/Ϫ and TRAF5 ϩ/ϩ / LDLR Ϫ/Ϫ mice were allowed to adhere to serum-coated glass coverslips and stained with phalloidin. Both TRAF5-deficient and -competent cells spread over time. Interestingly, TRAF5-deficient leukocytes formed significantly more raffles, suggesting that TRAF5 deficiency promotes actin polymerization (Online Figure II) .
TRAF5 Deficiency Does Not Alter Levels of Inflammatory Cytokines but Reduces T Regulatory Cells
Because differences in inflammatory gene expression and/or T-cell and macrophage subtypes may greatly influence atherogenesis, we also characterized these features. With inflammatory mediators being below the detection limit in mice on HCD, we challenged mice with intraperitoneal injection of TNF␣. Under these conditions, TRAF5
Ϫ/Ϫ / 
LDLR
Ϫ/Ϫ mice expressed similar amounts of TNF␣, IL-6, interferon-␥, IL-10, and IL-12p70 in serum and arterial tissue (Online Figure III, A and B) . We further analyzed leukocyte and monocyte subsets in the spleen and blood of these mice (Online Figure III, 
C and D). We found no difference in numbers of B cells (CD20), CD4
ϩ and CD8 ϩ T cells, monocytes, Ly6c high (Gr1 high ) and Ly6c low (Gr1 low ) monocytes, and neutrophils. In contrast, the spleens of TRAF5 Ϫ/Ϫ / LDLR Ϫ/Ϫ mice challenged with TNF␣ had fewer regulatory T cell (T reg ) cells. Because differences in T cell function may also modulate the atherogenic response, we tested T cell proliferation and activation. Interestingly, both CD4 ϩ and CD8 ϩ T cells from TRAF5 Ϫ/Ϫ /LDLR Ϫ/Ϫ animals proliferated more than those of respective controls animals. This coincided with increased T cell activation (CD44 high , CD62L low ) and proliferation markers (KLRG-1) in TRAF5-deficient CD8
ϩ T cells at baseline and following mild stimulation with ␣CD3/CD28 (Online Figure IV, A and B) .
However, on stimulation with ␣CD3/CD28 for 3 days, these cells did not produce different amounts of TNF␣, IL-2, and interferon-␥, suggesting no relevant bias in T helper cell 1/2 (Th1/Th2) cytokine expression in these animals (Online Figure IVC) .
TRAF5 Deficiency Enhances JNK Activation
We observed increased JNK activation following 10 minutes of TNF␣ stimulation in TRAF5-deficient ECs compared with controls, whereas ERK and p38 phosphorylation remained unchanged (Online Figure V, A 
TRAF5 Deficiency Modulates Atherogenesis Independently of TRAF2
Because TRAF2 has been suggested to compensate certain functions of TRAF5, we evaluated the role of TRAF2 in atherosclerosis-prone mice. Because exploration of atherogenesis in TRAF2-deficient mice was hampered by the limited viability of homozygous TRAF2-deficient mice, we performed FLC transplantations. Irradiated TRAF2 ϩ/ϩ / LDLR Ϫ/Ϫ and TRAF2
Ϫ/Ϫ FLC developed lesions of similar size and lipid content in the aortic root as respective control animals (NՆ16, Figure 7A and 7B). Expression levels of TRAF2 in aortas and spleens of TRAF5-deficient and -competent mice did not significantly differ from respective controls, corroborating the notion that the effects observed in TRAF5-deficient mice are not mediated by TRAF2 ( Figure 7C ).
TRAF5 mRNA Expression Decreases in Blood of Patients With Acute and Chronic Coronary Heart Disease
To extend our results obtained in mice to humans we tested the hypothesis that TRAF5 expression in blood correlates with stable and/or acute coronary heart disease in humans. Because TRAF5 is an intracellular protein, we quantified TRAF5 mRNA in total blood RNA of 325 patients undergoing coronary angiography divided into three groups: no coronary heart disease (No CHD), stable coronary heart disease (CHD), and acute coronary syndrome (ACS). Gender and body mass index did not significantly differ among the groups, whereas patients were older in the CHD group and had more traditional cardiovascular risk factors in the CHD and ACS groups (Online Table II ). TRAF5/GAPDH mRNA ratios were lower in patients with ACS (0.023Ϯ0.0018) and CHD (0.026Ϯ0.0016) compared with patients without coronary heart disease (0.029Ϯ0.0017, Pϭ0.018 and Pϭ0.017, respectively; Figure 8A ). Twelve patients with lowest TRAF5/GAPDH ratios were retested after a mean follow up of 30.8Ϯ1.8 months. Interestingly, we observed a rise in TRAF5/GAPDH levels at follow up, suggesting normalization of these ( Figure 8B ). Analysis of cellular blood components revealed higher TRAF5 expression in monocytes and lymphocytes compared with neutrophils, suggesting that these cell types contribute most to TRAF5 expression in blood ( Figure 8C ).
Discussion
This study reports the novel and surprising finding that TRAF5 deficiency promotes murine atherogenesis in vivo. These data challenge the common view of TRAF5 as a proinflammatory mediator by demonstrating antiinflammatory action of TRAF5 in atherogenesis.
Previous studies postulated a redundant role of TRAF5 and TRAF2 in NFB activation, suggesting that TRAF5 participates in TNF␣-induced NFB stimulation. 19 Other reports implicated TRAF5 in carcinogenesis attributable to augmented levels in splenic marginal zone lymphoma 30 and also in Hodgkin-Reed-Sternberg cell signaling. 31 However, participation of TRAF5 in atherosclerosis has been unexplored. Our study revealed enhanced atherosclerotic lesion formation in TRAF5-deficient mice. Beyond a mere increase in size, these plaques also contain more macrophages and lipids, characteristics commonly associated with more inflamed plaques with features associated with thrombosis in humans. 27 Based on these findings, we examined leukocyte extravasation as a likely underlying mechanism for increased macrophage content in the atherosclerotic plaque of TRAF5-deficient mice. Previous reports implicated TRAFs, specifically TRAF1 and -6, with the recruitment of leukocytes to inflamed tissue. [12] [13] [14] In accord with our data, So et al demonstrated that on induction of an asthma-like response TRAF5 deficiency aggravated airway inflammation. 32 This coincided (just as observed in our study) with enhanced expression of ICAM-1 on TRAF5-deficient ECs. ICAM-1 has previously been reported to be slightly elevated in TRAF5-deficient mice and even more so in mixed embryonic fibroblasts of TRAF2/TRAF5 double-deficient mice under basal and TNF␣-stimulated conditions. 33 Additionally, we found increased VCAM-1 expression in TRAF5-deficient aortas. In addition, we identified enhanced production of chemokines such as KC and MCP-1 in TRAF5-deficient mice. Chemokines attract leukocytes to inflammation sites and boost firm adhesion by activating integrins. These features render MCP-1 and KC proatherogenic. 34, 35 One of the hallmarks in atherogenesis is the formation of foam cells. Usually, macrophages imbibe lipids via their scavenger receptors and become foam cells. We describe here the involvement of TRAF5 in lipid uptake. More foam cell formation may contribute to the exacerbated atherosclerosis observed in TRAF5 Ϫ/Ϫ /LDLR Ϫ/Ϫ mice in this study. 34 Imbalance in the ratio of T-cell subgroups, as well as in their effector cytokines, can modulate atherogenesis in mice. 36 So et al recently reported increased Th2 cytokine production in TRAF5-deficient T cells after ␣CD27/␣CD3 stimulation in vitro. 32 Typical Th2 cytokines such as IL-10 and IL-5 may mitigate atherogenesis. 37 The present study found no difference in IL-10 expression in blood and arterial tissue, as well as no Th1/Th2 bias in T cells, after ␣CD27/ ␣CD3 stimulation. Several studies support that CD4 ϩ T cells play a crucial role in atherogenesis. 36 In accord with Nakano et al, CD4
ϩ and CD8 ϩ T cell ratios were similar between TRAF5 Ϫ/Ϫ /LDLR Ϫ/Ϫ and TRAF5 ϩ/ϩ /LDLR ϩ/ϩ mice. 22 
However, TRAF5
Ϫ/Ϫ /LDLR Ϫ/Ϫ had significantly lower T reg cell numbers when challenged with TNF␣, a finding that may contribute to augmented atherosclerosis observed in these mice. 38 TRAF6 also alters the homeostasis of T reg cells, and Lutgens et al recently demonstrated skewing of the immune response in mice with defective CD40-TRAF6 signaling toward a Th2 profile. 13 Interestingly, in contrast to previous reports, we found increased proliferation and activation of TRAF5-deficient T cells, a finding that may also account for some of the increased atherosclerosis observed in our model. However, this is not very likely because T cells numbers in plaques were similar in both groups.
Several reports suggested that TRAF2 may compensate for certain TRAF5-dependent functions. This may explain the rather mild phenotype of TRAF5-deficient mice. In our model, there was only a trend toward more TRAF2 expression in TRAF5-deficient aortas, whereas splenocytes expressed similar amounts in both groups. Our data are in accord with Nakano and colleagues, also showing that TRAF5 deficiency did not affect TRAF2 expression in vivo and in vitro. 15, 22 To rule out that the slight increase in TRAF2 expression in aortas in our study may account for the increased atherosclerosis observed in this study, TRAF2 function was tested in the LDLR Ϫ/Ϫ model, revealing no modulation of atherogenesis in vivo. Mechanistically, our signaling data suggest that enhanced JNK activation in TRAF5-deficient ECs and macrophages may mediate some of the effects observed. Macrophage JNK2 deletion was previously reported to suffice to reduce atherogenesis and foam cell formation in mice. 39 In contrast to our data, Nakano et al 22 reported similar activation of JNK in TRAF5-deficient and -competent fibroblasts, whereas Kraus et al 20 found decreased activation in B cells following CD40 stimulation. Interestingly, in our study, JNK was more activated in ECs, macrophages, and, by trend, also in aortas of TRAF5-deficient animals, whereas it tended to be less activated in splenocytes and resident peritoneal cells, the latter being predominant reservoirs for lymphocytes, suggesting a cell type-specific TRAF5-dependent regulation of JNK activation. It may very well be that increased JNK activation in TRAF5-deficient macrophages and ECs mediates some of the proatherogenic functions observed in this study, whereas a decreased JNK activation in lymphocytes mediates some of the immunologic effects of TRAF5 previously observed.
To test the hypothesis that TRAF5 may also associate with clinical disease, we performed a pilot clinical study in 325 patients undergoing coronary angiography. Intriguingly, TRAF5/GAPDH mRNA ratios significantly decreased in the blood of patients with chronic and acute coronary heart disease. These preliminary data support the notion that TRAF5 represents a protective marker in atherosclerosis.
In summary, the present study identifies TRAF5 as an antiinflammatory modulator in murine atherosclerosis. TRAF5 deficiency accelerates atherogenesis, most likely by promoting increasing leukocyte recruitment to the vessel wall and enhancing foam cell formation. Our findings shed new light on the functional role of TRAFs in chronic inflammatory diseases such as atherosclerosis and may ultimately give rise to the development of novel therapeutic options in atherosclerosis.
Novelty and Significance
What Is Known?
• Tumor necrosis factor receptor-associated factors (TRAFs) mediate signaling for a variety of cytokines previously implicated in chronic inflammatory diseases such as atherosclerosis.
• TRAF5 is overexpressed in atherosclerotic lesions and mediates proinflammatory gene expression in cells commonly found in the atheromata.
• TRAF5 promotes NFB and JNK signaling in lymphocytes, suggesting that it is a proinflammatory mediator in these cell types.
What New Information Does This Article Contribute?
• TRAF5 deficiency accelerates atherogenesis in mice, suggesting that TRAF5 signaling may be antiinflammatory and atheroprotective in this context in vivo.
• Mechanistically, deficiency of TRAF5 enhances adhesion of inflammatory cells to the endothelium and promotes lipid uptake.
• Accordingly, patients with stable or acute coronary heart disease express significantly lower amounts of TRAF5 mRNA in blood compared with healthy controls.
It is well accepted that atherosclerosis is an inflammatory disease. Several members of the TNF/IL-1/Toll-like receptor superfamily have been implicated in atherogenesis. Unfortunately, unselective inhibition of cytokines such as CD40L, although clinically effective, is associated with undesired side effects, limiting their therapeutic potential. Modulation of central signaling molecules such as TRAFs that bundle downstream signaling in a function-specific manner may potentially overcome some of these limitations. The present study demonstrates that TRAF5-deficient mice develop greater and more inflamed atherosclerotic lesions, identifying TRAF5 signaling as potential antiinflammatory and antiatherosclerotic event. Our data challenge previous reports that suggest a proinflammatory role of TRAF5 in lymphocytes; this emphasizes the importance of evaluating such molecules in vivo. In line with our findings in mice, patients with stable or acute coronary heart disease have lower levels of TRAF5 mRNA in their blood compared with healthy controls. These data suggest enhancement of TRAF5 signaling as a potential new therapeutic strategy for atherosclerosis and other chronic inflammatory diseases. Further studies could focus on ways to specifically and selectively modulate this signaling pathway.
